Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy
Cipolla BG, Mandron E, Lefort JM, Coadou Y, Della Negra E, Corbel L, Le Scodan R, Azzouzi AR, Mottet N
Cancer prevention research (Philadelphia, Pa.) · 96 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
- Intake measured by
- Not stated
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2015-05-12 · Cancer Prev Res (Phila) · vol. 8 · issue 8 · pp. 712–719
- Publisher
- American Association for Cancer Research
- Cited
- 131 citations · more than 97% of similar papers · 5.8× the field average
- Impact
- Top 10% most cited in its field
- References
- 54 works
- Access
- Paywalled
- Research areas
- Genomics, phytochemicals, and oxidative stress · Estrogen and related hormone effects · Reproductive System and Pregnancy
- Keywords
- Sulforaphane, Placebo, Urology, Medicine, Prostate cancer, Prostatectomy, Clinical endpoint, Randomized controlled trial, Placebo-controlled study, Internal medicine, Cancer, Pathology, Double blind
- MeSH
- humans, prostatic neoplasms, neoplasm recurrence, local, postoperative complications, isothiocyanates, sulfoxides, prostate-specific antigen, anticarcinogenic agents, neoplasm staging, prognosis, prostatectomy, follow-up studies, pilot projects, double-blind method, aged, male, neoplasm grading
9 authors
From FR
- Bernard G. Cipolla
- E. Mandron
- Jean Marc Lefort
- Yves CoadouHôpital Saint-Michel
- Emmanuel Della NegraCentre Hospitalier de Saint-Brieuc
- Luc CorbelCentre Hospitalier de Saint-Brieuc
Abstract
Increases in serum levels of prostate-specific antigen (PSA) occur commonly in prostate cancer after radical prostatectomy and are designated "biochemical recurrence." Because the phytochemical sulforaphane has been studied extensively as an anticancer agent, we performed a double-blinded, randomized, placebo-controlled multicenter trial with sulforaphane in 78 patients (mean age, 69 ± 6 years) with increasing PSA levels after radical prostatectomy. Treatment comprised daily oral administration of 60 mg of a stabilized free sulforaphane for 6 months (M0-M6) followed by 2 months without treatment (M6-M8). The study was designed to detect a 0.012 log (ng/mL)/month decrease in the log PSA slope in the sulforaphane group from M0 to M6. The primary endpoint was not reached. For secondary endpoints, median log PSA slopes were consistently lower in sulforaphane-treated men. Mean changes in PSA levels between M6 and M0 were significantly lower in the sulforaphane group (+0.099 ± 0.341 ng/mL) than in placebo (+0.620 ± 1.417 ng/mL; P = 0.0433). PSA doubling time was 86% longer in the sulforaphane than in the placebo group (28.9 and 15.5 months, respectively). PSA increases >20% at M6 were significantly greater in the placebo group (71.8%) than in the sulforaphane group (44.4%); P = 0.0163. Compliance and tolerance were very good. Sulforaphane effects were prominent after 3 months of intervention (M3-M6). After treatment, PSA slopes from M6 to M8 remained the same in the 2 arms. Daily administration of free sulforaphane shows promise in managing biochemical recurrences in prostate cancer after radical prostatectomy.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.